A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7076 (2006.01) A61P 9/14 (2006.01) C12Q 1/34 (2006.01) C12Q 1/44 (2006.01) C12N 9/14 (2006.01) C12N 9/16 (2006.01)
Patent
CA 2684017
Aortic valve stenosis (AS) is a chronic process related to a progressive mineralization of the aortic root and valve cusps. We found in human AS valves a high level of expression and enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase- 1(ENPP-1), which correlated to the degree of mineralization. In vitro, inhibition of ENPP activity with ARL 67156 significantly reduced calcification of isolated valve interstitial cells through a decreased production of phosphate. In a rat model of cardiovascular calcification, ARL 67156 significantly reduced calcification of the aortic root and valve cusps. This is the first study to demonstrate that increased expression and activity of ENPP-1 promotes the mineralization process in AS valves. Hence, inhibition of ectonucleotidase may represent a novel target of therapy for this frequent and serious cardiovascular disease.
Mathieu Patrick
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Universite Laval
LandOfFree
Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1)... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2013093